TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
39.49
+1.50 (3.95%)
Apr 23, 2025, 4:00 PM EDT - Market closed
TG Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for TG Therapeutics stock have an average target of 40.67, with a low estimate of 22 and a high estimate of 55. The average target predicts an increase of 2.99% from the current stock price of 39.49.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 4, 2025.
Analyst Ratings
The average analyst rating for TG Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $55 | Strong Buy | Reiterates | $55 | +39.28% | Mar 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $55 | Strong Buy | Reiterates | $55 | +39.28% | Jan 15, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $30 → $43 | Buy | Maintains | $30 → $43 | +8.89% | Nov 25, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $49 → $55 | Strong Buy | Maintains | $49 → $55 | +39.28% | Nov 5, 2024 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $20 → $22 | Hold | Maintains | $20 → $22 | -44.29% | Nov 5, 2024 |
Financial Forecast
Revenue This Year
577.82M
from 329.00M
Increased by 75.63%
Revenue Next Year
798.38M
from 577.82M
Increased by 38.17%
EPS This Year
0.95
from 0.15
Increased by 532.40%
EPS Next Year
1.99
from 0.95
Increased by 109.37%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 677.1M | 933.8M | 1.2B | ||
| Avg | 577.8M | 798.4M | 986.5M | ||
| Low | 529.1M | 637.0M | 803.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 105.8% | 61.6% | 45.5% | ||
| Avg | 75.6% | 38.2% | 23.6% | ||
| Low | 60.8% | 10.2% | 0.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.46 | 2.68 | 3.15 | ||
| Avg | 0.95 | 1.99 | 2.59 | ||
| Low | 0.43 | 1.03 | 1.61 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 873.0% | 182.3% | 58.6% | ||
| Avg | 532.4% | 109.4% | 30.3% | ||
| Low | 187.5% | 8.5% | -19.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.